Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Monsanto Sells Posilac To Lilly

August 25, 2008 | A version of this story appeared in Volume 86, Issue 34

Monsanto will sell its Posilac bovine somatotropin business to Eli Lilly & Co. for $300 million. Elanco, Lilly's animal health division, has marketed the recombinant hormone, which is used to increase cow milk production, for Monsanto over the past 10 years outside the U.S. under a licensing agreement. The company, which still has a small dairy genomics business, had announced it wanted to sell the Posilac business to concentrate on its core agricultural seeds and traits business. Elanco is the seventh largest animal health company in the world.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.